TODD STRATEGY GROUP

Lobbying for GILEAD SCIENCES, INC. · American biotechnology company that researches, develops and commercializes drugs.

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · California · House · Senate · $80,000.00 income · posted Jan 20, 2026

Lobbying activity 1

Health Issues

Prescription drug payment reform. Supply Chain. 340B.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.